These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 1812426)

  • 1. Adverse events following vaccine or placebo injection in an efficacy trial of an outer membrane vesicle vaccine against group B meningococcal disease in Norwegian secondary schools 1988-1991.
    Aavitsland P; Bjune G; Aasen S; Halvorsen S
    NIPH Ann; 1991 Dec; 14(2):133-4; discussion 136-7. PubMed ID: 1812426
    [No Abstract]   [Full Text] [Related]  

  • 2. Results of an efficacy trial with an outer membrane vesicle vaccine against systemic serogroup B meningococcal disease in Norway.
    Bjune G; Grønnesby JK; Høiby EA; Closs O; Nøkleby H
    NIPH Ann; 1991 Dec; 14(2):125-30; discussion 130-2. PubMed ID: 1812425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The meningococcal serogroup B vaccine protection trial in Norway 1988-1991: trial surveillance by an independent group.
    Halvorsen S
    NIPH Ann; 1991 Dec; 14(2):135-6; discussion 136-7. PubMed ID: 1812427
    [No Abstract]   [Full Text] [Related]  

  • 4. The Norwegian meningococcal group B outer membrane vesicle vaccine: side effects in phase II trials.
    Nøkleby H; Feiring B
    NIPH Ann; 1991 Dec; 14(2):95-101; discussion 101-2. PubMed ID: 1812440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bactericidal antibodies after vaccination with the Norwegian meningococcal serogroup B outer membrane vesicle vaccine: a brief survey.
    Høiby EA; Rosenqvist E; Frøholm LO; Bjune G; Feiring B; Nøkleby H; Rønnild E
    NIPH Ann; 1991 Dec; 14(2):147-55; discussion 155-6. PubMed ID: 1812429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic work with suspected cases of systemic meningococcal disease in the Norwegian serogroup B vaccine protection trials.
    Holten E; Bruun JN; Hellum KB; Maeland JA
    NIPH Ann; 1991 Dec; 14(2):103-6; discussion 121-3. PubMed ID: 1812423
    [No Abstract]   [Full Text] [Related]  

  • 7. Design of clinical trials with an outer membrane vesicle vaccine against systemic serogroup B meningococcal disease in Norway.
    Bjune G; Closs O; Frøholm LO; Grønnesby JK; Høiby EA; Nøkleby H
    NIPH Ann; 1991 Dec; 14(2):81-91; discussion 91-3. PubMed ID: 1812439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba.
    Sierra GV; Campa HC; Varcacel NM; Garcia IL; Izquierdo PL; Sotolongo PF; Casanueva GV; Rico CO; Rodriguez CR; Terry MH
    NIPH Ann; 1991 Dec; 14(2):195-207; discussion 208-10. PubMed ID: 1812432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Production, characterization and control of MenB-vaccine "Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease.
    Fredriksen JH; Rosenqvist E; Wedege E; Bryn K; Bjune G; Frøholm LO; Lindbak AK; Møgster B; Namork E; Rye U
    NIPH Ann; 1991 Dec; 14(2):67-79; discussion 79-80. PubMed ID: 1812438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meningococcal serogroup B vaccine protection trial and follow-up studies in Chile. The Chilean National Committee for Meningococcal Disease.
    Zollinger WD; Boslego J; Moran E; Garcia J; Cruz C; Ruiz S; Brandt B; Martinez M; Arthur J; Underwood P
    NIPH Ann; 1991 Dec; 14(2):211-2; discussion 213. PubMed ID: 1812433
    [No Abstract]   [Full Text] [Related]  

  • 11. Immunoblotting studies of vaccinee and patient sera from a Norwegian serogroup B meningococcal vaccination trial.
    Wedege E; Bjune G; Frøholm LO; Høiby EA; Rosenqvist E
    NIPH Ann; 1991 Dec; 14(2):183-4; discussion 185-6. PubMed ID: 1812431
    [No Abstract]   [Full Text] [Related]  

  • 12. Human antibody responses after vaccination with the Norwegian group B meningococcal outer membrane vesicle vaccine: results from ELISA studies.
    Rosenqvist E; Høiby EA; Bjune G; Bryn K; Closs O; Feiring B; Klem A; Nøkleby H; Frølm LO
    NIPH Ann; 1991 Dec; 14(2):169-79; discussion 180-1. PubMed ID: 1687481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Norwegian meningococcal serogroup B outer membrane vesicle vaccine protection trials: case tracing, meningococcal antigen detection and serological diagnosis.
    Høiby EA; Bjune G; Frøholm LO; Eng J; Halstensen A; Rosenqvist E; Rønnild E; Wedege E
    NIPH Ann; 1991 Dec; 14(2):107-21; discussion 121-3. PubMed ID: 1812424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meningococcal strains isolated from teenage patients during the serogroup B vaccination trial in Norway: serotyping, serosubtyping, immunotyping and clonal analysis.
    Frøholm LO; Caugant DA; Holten E; Høiby EA; Rosenqvist E; Wedege E
    NIPH Ann; 1991 Dec; 14(2):139-43; discussion 144-6. PubMed ID: 1812428
    [No Abstract]   [Full Text] [Related]  

  • 15. Development of a second generation group B meningococcal vaccine.
    Frasch CE; Sacchi CT; Brandiolone MC; Vieiera VS; Leite LC
    NIPH Ann; 1991 Dec; 14(2):225-30; discussion 230-1. PubMed ID: 1812436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of aluminium hydroxide and meningococcal serogroup C capsular polysaccharide on the immunogenicity and reactogenicity of a group B Neisseria meningitidis outer membrane vesicle vaccine.
    Rosenqvist E; Høiby EA; Bjune G; Aase A; Halstensen A; Lehmann AK; Paulssen J; Holst J; Michaelsen TE; Nøkleby H; Frøholm LO; Closs O
    Dev Biol Stand; 1998; 92():323-33. PubMed ID: 9554288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The capsular polysaccharide of group B Neisseria meningitidis as a vehicle for vaccine development.
    Jennings HJ
    Contrib Microbiol Immunol; 1989; 10():151-65. PubMed ID: 2479499
    [No Abstract]   [Full Text] [Related]  

  • 18. Second generation meningococcal OMP-LPS vaccines.
    Poolman JT; van der Ley PA; Wiertz EJ; Hoogerhout P
    NIPH Ann; 1991 Dec; 14(2):233-41. PubMed ID: 1725922
    [No Abstract]   [Full Text] [Related]  

  • 19. No evidence for serosubtype-restricted protection among teenagers vaccinated with the Norwegian group B outer membrane vesicle vaccine.
    Wedege E; Nokleby H; Bjune G
    J Infect Dis; 1999 Jul; 180(1):242; author reply 242-3. PubMed ID: 10353890
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway.
    Bjune G; Høiby EA; Grønnesby JK; Arnesen O; Fredriksen JH; Halstensen A; Holten E; Lindbak AK; Nøkleby H; Rosenqvist E
    Lancet; 1991 Nov; 338(8775):1093-6. PubMed ID: 1682541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.